MedTrace Logo

Prevalence of COVID-19 Antibodies Kingman AZ

NCT04533360 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 566

Last updated 2022-03-31

No results posted yet for this study

Summary

The COVID-19 disease outbreak is a historic event that has challenged medical systems in the United States. Currently, most reports of confirmed cases rely on the testing of symptomatic patients. These estimates of confirmed cases miss individuals who have recovered from infection, with mild or no symptoms, and individuals with symptoms who have not been tested due to the limited availability of tests. We are conducting serology testing within the community for SARS-CoV-2-specific antibodies through a serologic test could give insight into past COVID-19 infections within our community.

Conditions

  • Covid19

Interventions

DIAGNOSTIC_TEST

VITROS Anti-SARS-CoV-2 IgG test

The VITROS Anti-SARS-CoV-2 IgG test is a lateral flow immunoassay produced by Ortho-Clinical Diagnostics Inc.

Sponsors & Collaborators

  • Kingman Regional Medical Center

    lead OTHER

Principal Investigators

  • Anthony J Santarelli, PhD · Kingman Healthcare Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-28
Primary Completion
2020-10-09
Completion
2021-05-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04533360 on ClinicalTrials.gov